Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II
Restart Life SciencesCSE: HEAL
Also known as: Nova Mentis Life Science, Nova Mentis
1 Drug Candidate1 Trial
Canadian biotech (formerly Nova Mentis Life Science, renamed November 2024) developing psilocybin therapy for Fragile X Syndrome and autism spectrum disorder. Lead candidate NM-1001 received Health Canada authorisation for a Phase IIA clinical trial, making it one of the few psilocybin programmes targeting neurodevelopmental conditions.
Drug Pipeline
1NM-1001
PsilocybinPhase II
Psilocybin for Fragile X Syndrome and autism spectrum disorder. Health Canada authorised Phase IIA trial.
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: HEAL
- Lead Stage
- Phase II
- Website
- Visit